vs
Side-by-side financial comparison of AVALON HOLDINGS CORP (AWX) and CHAMPIONS ONCOLOGY, INC. (CSBR). Click either name above to swap in a different company.
AVALON HOLDINGS CORP is the larger business by last-quarter revenue ($21.5M vs $15.0M, roughly 1.4× CHAMPIONS ONCOLOGY, INC.). CHAMPIONS ONCOLOGY, INC. runs the higher net margin — 1.8% vs -1.7%, a 3.4% gap on every dollar of revenue. On growth, AVALON HOLDINGS CORP posted the faster year-over-year revenue change (21.7% vs 11.5%). AVALON HOLDINGS CORP produced more free cash flow last quarter ($-166.0K vs $-2.0M). Over the past eight quarters, CHAMPIONS ONCOLOGY, INC.'s revenue compounded faster (11.8% CAGR vs 6.7%).
Avalon Hill Games Inc. is a game company that publishes wargames and strategic board games. It has also published miniature wargaming rules, role-playing games and sports simulations. It is a subsidiary of Hasbro, and operates under the company's "Hasbro Gaming" division.
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
AWX vs CSBR — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $21.5M | $15.0M |
| Net Profit | $-356.0K | $268.0K |
| Gross Margin | 17.1% | 51.7% |
| Operating Margin | 0.4% | 1.2% |
| Net Margin | -1.7% | 1.8% |
| Revenue YoY | 21.7% | 11.5% |
| Net Profit YoY | 28.4% | -63.2% |
| EPS (diluted) | — | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.5M | $15.0M | ||
| Q3 25 | $25.7M | $14.0M | ||
| Q2 25 | $20.3M | $12.4M | ||
| Q1 25 | $16.1M | $17.0M | ||
| Q4 24 | $17.6M | $13.5M | ||
| Q3 24 | $24.2M | $14.1M | ||
| Q2 24 | $23.1M | $14.0M | ||
| Q1 24 | $18.9M | $12.0M |
| Q4 25 | $-356.0K | $268.0K | ||
| Q3 25 | $1.9M | $-436.0K | ||
| Q2 25 | $274.0K | $-1.8M | ||
| Q1 25 | $-1.5M | $4.5M | ||
| Q4 24 | $-497.0K | $728.0K | ||
| Q3 24 | $1.8M | $1.3M | ||
| Q2 24 | $954.0K | $-109.0K | ||
| Q1 24 | $-979.0K | $-2.5M |
| Q4 25 | 17.1% | 51.7% | ||
| Q3 25 | 23.7% | 42.9% | ||
| Q2 25 | 20.6% | 41.1% | ||
| Q1 25 | 14.8% | 61.2% | ||
| Q4 24 | 17.5% | 44.9% | ||
| Q3 24 | 24.6% | 49.7% | ||
| Q2 24 | 22.1% | 48.2% | ||
| Q1 24 | 16.2% | 34.7% |
| Q4 25 | 0.4% | 1.2% | ||
| Q3 25 | 9.1% | -3.8% | ||
| Q2 25 | 3.7% | -16.2% | ||
| Q1 25 | -7.2% | 26.4% | ||
| Q4 24 | -0.8% | 5.4% | ||
| Q3 24 | 9.4% | 9.5% | ||
| Q2 24 | 6.3% | -1.9% | ||
| Q1 24 | -2.7% | -21.4% |
| Q4 25 | -1.7% | 1.8% | ||
| Q3 25 | 7.4% | -3.1% | ||
| Q2 25 | 1.4% | -14.9% | ||
| Q1 25 | -9.3% | 26.4% | ||
| Q4 24 | -2.8% | 5.4% | ||
| Q3 24 | 7.6% | 9.3% | ||
| Q2 24 | 4.1% | -0.8% | ||
| Q1 24 | -5.2% | -21.1% |
| Q4 25 | — | $0.02 | ||
| Q3 25 | — | $-0.03 | ||
| Q2 25 | — | $-0.12 | ||
| Q1 25 | — | $0.31 | ||
| Q4 24 | — | $0.05 | ||
| Q3 24 | — | $0.09 | ||
| Q2 24 | — | $-0.01 | ||
| Q1 24 | — | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.1M | $8.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $38.4M | $4.2M |
| Total Assets | $87.4M | $30.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.1M | $8.5M | ||
| Q3 25 | $4.6M | $10.3M | ||
| Q2 25 | $3.7M | $9.8M | ||
| Q1 25 | $1.3M | $3.2M | ||
| Q4 24 | $2.8M | $2.8M | ||
| Q3 24 | $3.9M | $2.9M | ||
| Q2 24 | $3.8M | $2.6M | ||
| Q1 24 | $1.2M | $4.5M |
| Q4 25 | $38.4M | $4.2M | ||
| Q3 25 | $38.7M | $3.5M | ||
| Q2 25 | $36.8M | $3.8M | ||
| Q1 25 | $36.5M | $5.5M | ||
| Q4 24 | $38.0M | $681.0K | ||
| Q3 24 | $38.5M | $-332.0K | ||
| Q2 24 | $36.7M | $-1.9M | ||
| Q1 24 | $35.7M | $-2.1M |
| Q4 25 | $87.4M | $30.2M | ||
| Q3 25 | $90.7M | $30.5M | ||
| Q2 25 | $88.1M | $32.3M | ||
| Q1 25 | $87.6M | $30.6M | ||
| Q4 24 | $86.2M | $25.2M | ||
| Q3 24 | $89.1M | $24.9M | ||
| Q2 24 | $91.7M | $26.1M | ||
| Q1 24 | $90.6M | $26.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $278.0K | $-1.7M |
| Free Cash FlowOCF − Capex | $-166.0K | $-2.0M |
| FCF MarginFCF / Revenue | -0.8% | -13.1% |
| Capex IntensityCapex / Revenue | 2.1% | 1.6% |
| Cash ConversionOCF / Net Profit | — | -6.47× |
| TTM Free Cash FlowTrailing 4 quarters | $2.1M | $5.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $278.0K | $-1.7M | ||
| Q3 25 | $1.5M | $600.0K | ||
| Q2 25 | $3.0M | $6.9M | ||
| Q1 25 | $-982.0K | $490.0K | ||
| Q4 24 | $-579.0K | $-283.0K | ||
| Q3 24 | $342.0K | $311.0K | ||
| Q2 24 | $3.2M | $-1.8M | ||
| Q1 24 | $411.0K | $-919.0K |
| Q4 25 | $-166.0K | $-2.0M | ||
| Q3 25 | $852.0K | $554.0K | ||
| Q2 25 | $2.7M | $6.6M | ||
| Q1 25 | $-1.4M | $448.0K | ||
| Q4 24 | $-1.1M | $-377.0K | ||
| Q3 24 | $-660.0K | — | ||
| Q2 24 | $2.9M | $-1.8M | ||
| Q1 24 | $56.0K | $-1.0M |
| Q4 25 | -0.8% | -13.1% | ||
| Q3 25 | 3.3% | 4.0% | ||
| Q2 25 | 13.5% | 53.5% | ||
| Q1 25 | -8.5% | 2.6% | ||
| Q4 24 | -6.4% | -2.8% | ||
| Q3 24 | -2.7% | — | ||
| Q2 24 | 12.4% | -13.0% | ||
| Q1 24 | 0.3% | -8.4% |
| Q4 25 | 2.1% | 1.6% | ||
| Q3 25 | 2.3% | 0.3% | ||
| Q2 25 | 1.4% | 2.0% | ||
| Q1 25 | 2.4% | 0.2% | ||
| Q4 24 | 3.1% | 0.7% | ||
| Q3 24 | 4.1% | 0.0% | ||
| Q2 24 | 1.5% | 0.0% | ||
| Q1 24 | 1.9% | 0.8% |
| Q4 25 | — | -6.47× | ||
| Q3 25 | 0.76× | — | ||
| Q2 25 | 11.07× | — | ||
| Q1 25 | — | 0.11× | ||
| Q4 24 | — | -0.39× | ||
| Q3 24 | 0.19× | 0.24× | ||
| Q2 24 | 3.35× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AWX
Segment breakdown not available.
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
